Can Quetiapine (Seroquel) Be Continued in Acute Kidney Injury?
Quetiapine should be discontinued immediately in patients with acute kidney injury, as atypical antipsychotics—particularly quetiapine—are associated with a significantly increased risk of worsening renal function, with a 73% increased risk of AKI hospitalization and the highest nephrotoxic potential among atypical antipsychotics. 1, 2
Evidence for Discontinuation in AKI
The nephrotoxic risk of quetiapine is well-established through multiple mechanisms:
Quetiapine carries the highest risk of renal impairment among all atypical antipsychotics, encompassing both acute kidney injury (RR 1.51) and chronic kidney disease (RR 1.23) 1
In older adults, atypical antipsychotic use is associated with a 73% increased risk of hospitalization with AKI (RR 1.73,95% CI 1.55-1.92), with consistent findings when assessed by serum creatinine elevation 2
A case report documented quetiapine-related AKI requiring continuous hemodiafiltration, with renal function improving only after drug discontinuation 3
The mechanism of quetiapine-induced AKI involves multiple pathways:
Orthostatic hypotension occurs in 4-7% of adults taking quetiapine, reducing renal perfusion pressure 4
Atypical antipsychotics cause acute urinary retention (RR 1.98), which can precipitate or worsen AKI 2
Hypotension associated with quetiapine use (RR 1.91) directly compromises renal blood flow 2
Drug Stewardship Principles in AKI
General nephrotoxic medication management guidelines apply directly to quetiapine:
Potentially nephrotoxic agents should be discontinued in AKI unless absolutely essential for life-threatening conditions 5
Each additional nephrotoxic medication increases AKI odds by approximately 53%, and quetiapine is classified among nephrotoxins 6, 7
The patient is already receiving aripiprazole and trazodone, creating a polypharmacy situation that increases overall nephrotoxic burden 5
Pharmacokinetic Considerations in Renal Impairment
Quetiapine pharmacokinetics are not significantly altered by renal impairment, but this does not eliminate the risk:
Oral clearance of quetiapine was not reduced in patients with renal impairment in pharmacokinetic studies 8
However, the FDA label notes that clinical experience with quetiapine in renal impairment is limited 4
Dosing regimens for chronic kidney disease should not be extrapolated to AKI due to altered hepatic blood flow, protein binding, and cytochrome P450 activity 7
Alternative Sedative Options During AKI
Safer alternatives exist for managing agitation or insomnia in AKI:
Trazodone is already being used in this patient and represents a safer option, though recent data show quetiapine has 3.1-fold higher mortality risk compared to trazodone in older adults 9
Low-dose benzodiazepines (lorazepam 0.25-0.5 mg or midazolam 0.5-1 mg) may be used for severe agitation in AKI, with careful monitoring for respiratory depression 5
Haloperidol at low doses (0.25-0.5 mg) can be considered if antipsychotic therapy is essential, though it also carries risks of QTc prolongation and extrapyramidal symptoms 5
Critical Safety Monitoring if Continuation is Considered
If quetiapine must be continued for a compelling psychiatric indication (which is unlikely given concurrent aripiprazole use):
Monitor blood pressure closely for orthostatic hypotension, maintaining mean arterial pressure >65 mmHg 6, 7
Assess for urinary retention daily, as this can precipitate or worsen AKI 2
Check serum creatinine and eGFR at least every 48-72 hours during the AKI episode 5
Reduce dose to 25 mg daily or less if continuation is deemed absolutely necessary, though this does not eliminate risk 4
Criteria for Potential Reintroduction After AKI Resolution
Quetiapine should only be restarted after ALL of the following conditions are met:
Volume status is optimized and hemodynamic stability achieved 6, 7
Renal function will be monitored within 1 week of restart 6, 7
Common Pitfalls to Avoid
Do not assume quetiapine is safe simply because it is being used at "low dose" for insomnia:
Low-dose quetiapine (typically 25-100 mg) for insomnia in older adults is associated with significantly higher rates of mortality (HR 3.1), dementia (HR 8.1), and falls (HR 2.8) compared to trazodone 9
The patient is already receiving trazodone, which provides sedation with lower nephrotoxic risk 9
Do not continue quetiapine based solely on unchanged pharmacokinetics in renal impairment:
- While quetiapine clearance is not reduced in renal impairment, the drug's hemodynamic effects (hypotension, urinary retention) directly worsen AKI through non-pharmacokinetic mechanisms 8, 2
Do not overlook the polypharmacy burden: